Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Elotuzumab (HuLuc63) Clear all
Completed Phase 2 Interventional Results available

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

NCT02969837
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Sep 30, 2026, 4:42 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

NCT02541643
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab
Drug
Lead sponsor
Sundar Jagannath
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Sep 30, 2026, 4:42 AM EDT
Terminated Phase 1Phase 2 Interventional

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

NCT04150965
View directory record Official record
Conditions
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
Interventions
Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-TIGIT, Anti-TIGIT + Pomalidimide + Dexamethasone
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Sep 30, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01729091
View directory record Official record
Conditions
Plasma Cell Leukemia, Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Natural Killer Cell Therapy, Umbilical Cord Blood-Derived Lymphocyte Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Sep 30, 2026, 4:42 AM EDT
Active, not recruiting Phase 2 Interventional

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

NCT04517851
View directory record Official record
Conditions
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
Interventions
Elotuzumab, Questionnaire Administration
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 30, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

NCT02726581
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Nivolumab, Elotuzumab, Pomalidomide, Dexamethasone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 30, 2026, 4:42 AM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT06232707
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Alnuctamab, Pomalidomide, Daratumumab, Elotuzumab, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Sep 30, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

NCT02252263
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lirilumab, Urelumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Little Rock, Arkansas • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Sep 30, 2026, 4:42 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

NCT03651128
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 30, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

NCT02612779
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
22
States / cities
Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Sep 30, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

NCT02843074
View directory record Official record
Conditions
Multiple Myeloma
Interventions
elotuzumab, Lenalidomide, Dexamethasone, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Denver, Colorado • Bethesda, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 30, 2026, 4:42 AM EDT
Terminated Phase 1 Interventional

FT538 in Subjects With Advanced Hematologic Malignancies

NCT04614636
View directory record Official record
Conditions
Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
Interventions
FT538, Cyclophosphamide, Fludarabine, Daratumumab, Elotuzumab
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Minneapolis, Minnesota • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 30, 2026, 4:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

Selinexor and Backbone Treatments of Multiple Myeloma Patients

NCT02343042
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 30, 2026, 4:42 AM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

NCT03411031
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 30, 2026, 4:42 AM EDT
Active, not recruiting Early Phase 1 Interventional

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT05560399
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Elotuzumab, Dexamethasone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Sep 30, 2026, 4:42 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
49
States / cities
Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 4:42 AM EDT
Withdrawn Phase 2 Interventional

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

NCT03168100
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 30, 2026, 4:42 AM EDT
Terminated Phase 1 Interventional

A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

NCT00726869
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab (HuLuc63)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 30, 2026, 4:42 AM EDT
Not listed Phase 2 Interventional

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

NCT03252600
View directory record Official record
Conditions
Recurrent Primary Amyloidosis
Interventions
Cyclophosphamide, Dexamethasone, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
Drug · Biological · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Duarte, California • Denver, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 30, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Sep 30, 2026, 4:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

NCT01668719
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
Interventions
Bortezomib, Dexamethasone, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide
Drug · Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
417
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Burbank, California + 261 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 30, 2026, 4:42 AM EDT
Recruiting Phase 3 Interventional

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
100
States / cities
Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 30, 2026, 4:42 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

NCT02718833
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 30, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

NCT02654132
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 30, 2026, 4:42 AM EDT